Valuation: Lobe Sciences Ltd.

Market Cap 29.96M 21.35M 19.05M 17.58M 15.97M 2.02B 30.42M 212M 83.42M 1.06B 80.13M 78.41M 3.36B P/E 2024
-0.55x
P/E 2025 -1.57x
Enterprise Value 22.69M 16.17M 14.43M 13.31M 12.1M 1.53B 23.04M 160M 63.18M 802M 60.69M 59.39M 2.54B EV / Sales 2024
36.2x
EV / Sales 2025 -
Free-Float
45.82%
Yield 2024 *
-
Yield 2025 -
1 week-30.00%
Current month-36.36%
1 month-46.15%
3 months-61.11%
6 months-69.57%
Current year-22.22%
1 week 0.04
Extreme 0.035
0.05
1 month 0.04
Extreme 0.035
0.08
Current year 0.04
Extreme 0.035
0.18
1 year 0.03
Extreme 0.03
0.18
3 years 0.01
Extreme 0.01
0.18
5 years 0.01
Extreme 0.01
0.39
10 years 0.01
Extreme 0.01
1.8
Manager TitleAgeSince
Chief Executive Officer 76 2024-08-11
Director of Finance/CFO - 2026-08-31
Chief Tech/Sci/R&D Officer - 2026-10-19
Director TitleAgeSince
Chairman 76 2024-08-11
Director/Board Member 78 2024-08-11
Director/Board Member 59 2024-08-11
Date Insider Type Main position Quantity % Market Cap. Importance
9/1/26 Other

Chief Financial Officer

0 0%
9/1/26 Other

Chief Financial Officer

0 0%
9/1/26 Other

Chief Financial Officer

0 0%
Change 5-day change 1-year change 3-year change Capi.($)
0.00%-30.00%-22.22%+75.00% 8.47M
+2.83%+4.40%+60.84%+123.50% 1,165B
+3.81%+5.66%+38.70%+74.91% 645B
+0.14%+0.63%+24.71%+95.03% 504B
-0.38%+2.85%+43.59%+64.18% 380B
-1.76%+1.41%+68.06%+43.41% 363B
-0.71%+2.21%+21.95%+50.84% 297B
-1.78%+2.21%+1.80%+25.95% 269B
+2.04%+3.05%+51.12%+60.42% 237B
+2.36%-0.11%+29.42%+102.04% 195B
Average -0.17%-0.71%+31.80%+71.53% 405.55B
Weighted average by Cap. -0.47%+3.17%+43.01%+82.98%

Financials

2024 2025
Net sales 136K 97.05K 86.62K 79.91K 72.6K 9.19M 138K 963K 379K 4.82M 364K 356K 15.26M -
Net income -4.42M -3.15M -2.81M -2.59M -2.36M -298M -4.49M -31.25M -12.31M -156M -11.82M -11.57M -495M -4.43M -3.15M -2.82M -2.6M -2.36M -299M -4.5M -31.3M -12.33M -157M -11.84M -11.59M -496M
Net Debt 1.5M 1.07M 952K 879K 798K 101M 1.52M 10.59M 4.17M 52.96M 4.01M 3.92M 168M -7.27M -5.18M -4.62M -4.26M -3.87M -490M -7.38M -51.37M -20.23M -257M -19.44M -19.02M -814M
Projected Income Statement - Annual - Lobe Sciences Ltd.
Logo Lobe Sciences Ltd.
Lobe Sciences, Ltd. is a biopharmaceutical company focused on using lipid technology to develop treatments for orphan and rare diseases. The Company, through its wholly owned subsidiaries, Alera Pharma, Inc. and Altemia, Inc., is advancing the development of a patented drug candidate aimed at treating neurological disorders, with an initial focus on chronic cluster headache (Alera). The Company commercializes Altemia MF, a medical food designed to manage deficiencies commonly found in sickle cell disease. Additionally, through Cynaptec Pharmaceuticals, Inc. (Cynaptec), the Company retains an interest in developing Conjugated Psilocin in neurology and psychiatric indications. Conjugated Psilocin is a patented, oral, stable analog of psilocin, the active metabolite of the prodrug psilocybin, designed to enhance bioavailability and therapeutic efficacy, which has been identified as having therapeutic potential in a variety of neurological conditions.
Employees
-
Date Price Change Volume
26-10-22 $0.0350 -30.00% 993,068
26-10-21 $0.0500 0.00% 47,000
26-10-20 $0.0500 0.00% 33,000
26-10-19 $0.0500 0.00% 8,000
26-10-15 $0.0500 +11.11% 31,000
  1. Stock Market
  2. Stocks
  3. LOBE Stock